Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XenoPort XNPT

Healthcare Biotechnology
"XenoPort Inc is a biopharmaceutical company. It is engaged in developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders."

Recent & Breaking News (NDAQ:XNPT)

XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder

Business Wire June 25, 2015

HORIZANT (gabapentin enacarbil) Included in New Expert Recommendations on Prevention and Treatment of RLS Augmentation

Business Wire June 8, 2015

XenoPort to Present New Pooled Data Analyses on HORIZANT (gabapentin enacarbil) at the 2015 SLEEP Annual Meeting

Business Wire June 2, 2015

XenoPort to Present at the Jefferies 2015 Global Healthcare Conference

Business Wire May 18, 2015

XenoPort to Present New HORIZANT (gabapentin enacarbil) Data at the American Pain Society 34th Annual Scientific Meeting

Business Wire May 7, 2015

XenoPort Reports First Quarter Financial Results

Business Wire May 6, 2015

XenoPort to Release First Quarter Financial Results on May 6, 2015

Business Wire April 28, 2015

XenoPort to Present New Data Analyses for HORIZANT (gabapentin enacarbil) at the 67th Annual Meeting of the American Academy of Neurology

Business Wire April 15, 2015

XenoPort to Present at the Cowen and Company 35th Annual Health Care Conference

Business Wire February 23, 2015

XenoPort Reports Fourth Quarter and Year-End 2014 Financial Results

Business Wire February 19, 2015

XenoPort to Present at the RBC Capital Markets' Global Healthcare Conference

Business Wire February 18, 2015

XenoPort to Release Fourth Quarter and Year-End Financial Results on February 19, 2015

Business Wire February 5, 2015

XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022

Business Wire January 29, 2015

XenoPort Announces Proposed Offering of $100 Million Convertible Senior Notes due 2022

Business Wire January 28, 2015

XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder

Business Wire January 11, 2015

XenoPort to Present at the Credit Suisse Healthcare Conference

Business Wire November 6, 2014

XenoPort Reports Third Quarter Financial Results

Business Wire November 4, 2014

XenoPort to Release Third Quarter Financial Results on November 4

Business Wire October 23, 2014

XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston

Business Wire September 10, 2014

XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder

Business Wire September 9, 2014